Paper Details

  1. Home
  2. Paper Details

Three months of rifapentine and isoniazid for latent tuberculosis infection.

Author: , Bliven-SizemoreErin, BorisovAndrey S, BozemanLorna, ChaissonRichard E, CondeMarcus B, GordinFred, HackmanJudith, HamiltonCarol Dukes, HorsburghC Robert, KerriganAmy, MenziesDick, ShangNong, SterlingTimothy R, VillarinoM Elsa, WeinerMarc, WeisStephen E, WingDiane

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A 3-month regimen of rifapentine plus isoniazid was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion. METHODS: We conducted an op...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1104875

データ提供：米国国立医学図書館（NLM）

Latent Tuberculosis Infection: A Silent Threat in the Desert

Tuberculosis (TB) is a serious infectious disease that can have devastating consequences. Imagine a hidden oasis in the desert, where the threat of TB lies dormant. This research examines the effectiveness of a new treatment regimen for latent TB infection, using rifapentine and isoniazid for 3 months. The authors compare this shorter regimen to the standard 9-month regimen of isoniazid, assessing its efficacy and safety. This study provides valuable insights into the development of more convenient and effective treatment strategies for latent TB infection.

Shorter Treatment, Greater Impact: A New Path Through the Desert

The study found that the 3-month regimen of rifapentine and isoniazid was as effective as the standard 9-month regimen of isoniazid alone in preventing TB. Imagine a shorter journey through the desert, reaching the oasis of health more quickly. This research suggests that a shorter treatment regimen may be a viable option for managing latent TB infection.

Protecting Against TB: A Desert Oasis of Health

This research highlights the importance of treating latent TB infection to prevent active disease. Picture a desert oasis, a sanctuary free from the threat of TB. This study emphasizes the need for effective treatment strategies to protect individuals from the devastating consequences of this infectious disease.

Dr. Camel's Conclusion

Latent TB infection is a significant public health concern. This research provides evidence for a shorter and more convenient treatment regimen, offering hope for a more effective and accessible approach to TB prevention. The desert of TB can be a dangerous place, but with knowledge and innovation, we can find new ways to protect ourselves and our communities from this silent threat.

Date :
  1. Date Completed 2011-12-20
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

22150035

DOI: Digital Object Identifier

10.1056/NEJMoa1104875

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.